(0.91%) 5 064.20 points
(0.85%) 38 226 points
(1.51%) 15 841 points
(0.27%) $79.16
(-0.59%) $2.02
(0.10%) $2 312.00
(0.23%) $26.89
(0.09%) $963.50
(0.01%) $0.932
(-0.02%) $10.99
(-0.01%) $0.798
(-0.02%) $91.11
3 days till quarter result
(bmo 2024-05-06)
Expected move: +/- 8.01%
@ $24.09
Utstedt: 14 feb 2024 @ 21:43
Avkastning: -8.43%
Forrige signal: feb 13 - 21:46
Forrige signal:
Avkastning: 0.75 %
Live Chart Being Loaded With Signals
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease...
Stats | |
---|---|
Dagens volum | 1.04M |
Gjennomsnittsvolum | 767 552 |
Markedsverdi | 953.55M |
EPS | $0 ( 2024-04-29 ) |
Neste inntjeningsdato | ( $-0.510 ) 2024-05-06 |
Last Dividend | $5.25 ( 2012-12-13 ) |
Next Dividend | $0 ( N/A ) |
P/E | -9.51 |
ATR14 | $0.0140 (0.06%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-26 | Robertson Sanford | Buy | 69 000 | Common Stock |
2024-01-03 | Robertson Sanford | Buy | 354 740 | Common Stock Warrant |
2024-04-26 | Robertson Sanford | Sell | 46 000 | Common Stock Warrant |
2024-01-03 | Robertson Sanford | Buy | 72 000 | Common Stock Warrant |
2024-04-23 | Barry Richard | Buy | 176 085 | Common Stock |
INSIDER POWER |
---|
71.90 |
Last 91 transactions |
Buy: 2 502 072 | Sell: 652 285 |
Volum Korrelasjon
Cassava Sciences Inc Korrelasjon
10 Mest positive korrelasjoner | |
---|---|
CBIO | 0.848 |
GOOD | 0.844 |
ALXO | 0.828 |
ANGN | 0.828 |
CTBI | 0.825 |
MIRO | 0.819 |
RPRX | 0.813 |
CMPX | 0.813 |
DCRC | 0.808 |
BLUE | 0.806 |
10 Mest negative korrelasjoner | |
---|---|
RNA | -0.87 |
VKTX | -0.844 |
BWMX | -0.833 |
MTRY | -0.832 |
DKDCA | -0.826 |
CFFE | -0.823 |
ROCL | -0.821 |
LRMR | -0.821 |
AMPH | -0.814 |
EDTX | -0.811 |
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Cassava Sciences Inc Korrelasjon - Valuta/Råvare
Cassava Sciences Inc Økonomi
Annual | 2023 |
Omsetning: | $0 |
Bruttogevinst: | $-1.53M (0.00 %) |
EPS: | $-2.32 |
FY | 2023 |
Omsetning: | $0 |
Bruttogevinst: | $-1.53M (0.00 %) |
EPS: | $-2.32 |
FY | 2022 |
Omsetning: | $-1 800.00 |
Bruttogevinst: | $-1.30M (72 377.78 %) |
EPS: | $-1.800 |
FY | 2021 |
Omsetning: | $0.00 |
Bruttogevinst: | $0.00 (0.00 %) |
EPS: | $-0.820 |
Financial Reports:
No articles found.
Cassava Sciences Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $14.00 | 2010-12-13 |
Last Dividend | $5.25 | 2012-12-13 |
Next Dividend | $0 | N/A |
Payout Date | 2012-12-24 | |
Next Payout Date | N/A | |
# dividends | 2 | -- |
Total Paid Out | $19.25 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.22 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2010 | $14.00 | 37.20% |
2011 | $0 | 0.00% |
2012 | $5.25 | 19.20% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -40.28 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.624 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -0.560 | 1.500 | -7.33 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 9.13 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 8.60 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 8.53 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | -1.944 | 2.00 | -0.648 | -1.296 | [0 - 30] |
freeCashFlowPerShareTTM | -1.954 | 2.00 | -0.977 | -1.954 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.348 | 1.000 | 7.53 | 7.53 | [0.2 - 0.8] |
operatingProfitMarginTTM | -45.29 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0.0155 | 0.800 | -3.23 | -2.58 | [0.5 - 2] |
Total Score | -1.853 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -9.88 | 1.000 | -1.099 | 0 | [1 - 100] |
returnOnEquityTTM | -0.560 | 2.50 | -4.71 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -1.954 | 2.00 | -0.651 | -1.954 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -1.944 | 2.00 | -0.648 | -1.296 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.0432 | 1.500 | -3.62 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -34.93 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -2.91 |
Cassava Sciences Inc
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.